Michael Taravella, MD
Cornea and External Diseases Specialist · Aurora, CONPI 1477631737
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 46.7% of the total. Reporting peaked in 2019 at $5,690 and has fallen 96.2% since, to $217 in 2025.
Across 62 payments — averaging $196.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$6K
- Harrow Eye, LLC$1K
- Eyevance Pharmaceuticals LLC$1K
- Alcon$1K
- Bausch & Lomb Americas Inc.$550
- Oyster Point Pharma, Inc.$374
- plus $2K from 9 others
What the payments were for
- Consulting fees$6,50053%
- Speaking & faculty fees$6005%
- Food & beverage$5,08542%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 7 | $5,685 |
| Harrow Eye, LLC | 10 | $1,345 |
| Eyevance Pharmaceuticals LLC | 5 | $1,332 |
| Alcon | 14 | $1,292 |
| Bausch & Lomb Americas Inc. | 4 | $550 |
| Oyster Point Pharma, Inc. | 2 | $374 |
| Carl Zeiss Meditec USA, Inc. | 2 | $304 |
| Kala Pharmaceuticals, Inc. | 2 | $257 |
| Sun Pharmaceutical Industries Inc. | 5 | $257 |
| Dompe US, Inc. | 2 | $208 |
| Novartis | 3 | $164 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $141 |
| Omeros Corporation | 1 | $125 |
| Ocular Therapeutix, Inc. | 3 | $107 |
| Eyepoint US, Inc. | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDesign Advanced Wavescan Studio$1,750
- Flarex$1,250
- VEVYE$1,017
- enVista MX60 IOL$700
- Clareon$519
- TYRVAYA$374
- VisuMax$304
- AcrySof$273
- EYSUVIS$257
- STELLARIS$249
- Tecnis IOL$187
- enVista Aspire IOL$150
- IC-8 Apthera IOL$147
- Tecnis Simplicity$147
- MIEBO$145
- XIIDRA$145
- ENVISTA TORIC$141
- VICTUS$141
- ReSTOR$140
- INVELTYS$136
How this compares
Too few cornea and external diseases specialist providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 85 | $124,760 |
| Cyclosporine | 32 | $22,262 |
| Loteprednol Etabonate | 72 | $20,065 |
| Prednisolone Acetate | 503 | $17,692 |
| Fluorometholone | 192 | $16,617 |
| Ketorolac Tromethamine | 300 | $12,048 |
| ZirganGanciclovir | 17 | $8,131 |
| DurezolDifluprednate | 13 | $6,398 |
| TobradexTobramycin/Dexamethasone | 13 | $4,469 |
| MoxifloxacinMoxifloxacin Hcl | 168 | $4,125 |
| ValacyclovirValacyclovir Hcl | 46 | $2,363 |
| Difluprednate | 12 | $1,171 |
| Dexamethasone Sodium Phosphate | 14 | $845 |
| Brimonidine Tartrate | 64 | $752 |
| ErythromycinErythromycin Base | 61 | $715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $141 | $20,06572 claims |
| Bausch & Lomb Americas Inc.Zirgan | $550 | $8,13117 claims |
| NovartisDurezol | $164 | $6,39813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Aurora
- Karen ChristopherAurora$3K
- Christopher GelstonAurora$2K
- Michael WildesAurora$1K
- Brittany PerziaAurora$956
- Aimee VernerLongmont$3K
- Christopher HamptonWheat Ridge$1K
- Ronald WiseDenver$1K
- James SbarbaroColorado Springs$1K
- Clayton FalknorColorado Springs$1K
- Marcus NeufferUsaf Academy$445
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.